171 results
Page 2 of 9
8-K
EX-10.4
p2uqx8m umx6ov
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
d14 53r06pg
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
EX-23.2
1fkyoyltn
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
EX-23.1
y6rxxpui
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4/A
aw77c71re pc
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
EX-23.2
dwfgf2l0tqy2zuztt6u
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
EX-23.1
53xlj5kh8nx3u4 hy
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
a85y3 kvv
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
ws9ri 8353l4
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
xdh8pn4 gno7mjubt
9 Sep 22
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
7:14am
8-K
EX-10.1
uap3k6ebvu1mpb
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
424B5
nmgkp
28 Apr 22
Prospectus supplement for primary offering
8:09am